
This episode explores Tesamorelin, a synthetic peptide that activates the body's own growth hormone release, its mechanism, and its implications for health.
In the mid-1990s, antiretroviral therapy was transforming HIV from a death sentence into a chronic condition — and creating an unexpected syndrome in its wake. Patients on the new combinations were developing visceral fat accumulation, peripheral fat loss, dyslipidaemia, and a measurably blunted growth hormone rhythm. A small Canadian biotech in Montréal saw the lever. Native GHRH had a half-life of seven minutes, cleaved almost instantly by an enzyme called DPP-IV. Their structural innovation — adding a single trans-3-hexenoic acid group to the N-terminus — blocked the cleavage site, extended the half-life to twenty-six minutes, and made an entire pharmacology clinically viable. That compound is Tesamorelin, and in 2010 it became one of the very few synthetic peptides ever to clear the full FDA approval pathway. In this episode, Dr. Ethan walks through the molecule properly. The forty-four amino acid sequence, the structural modification that makes it work, and the mechanism that distinguishes it from every other growth hormone strategy: Tesamorelin doesn't introduce GH, it activates the body's own pituitary to release GH in its natural pulsatile pattern, preserving somatostatin…
Explore listener stats, chart rankings, contacts and more on the The Science of Age-less Living podcast page.